{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T02:46:16Z","timestamp":1782269176244,"version":"3.54.5"},"reference-count":38,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background: Hemophilia care has undergone a major therapeutic transformation with the introduction of extended half-life products, non-replacement therapies, and gene therapy. However, the benefits of these advances are not equally distributed worldwide, and their impact on long-term musculoskeletal outcomes remains uncertain. Objective: To analyze global disparities in hemophilia care and research production in the context of recent therapeutic advances, with particular attention to musculoskeletal management, physiotherapy, and scalable strategies for resource-limited settings. Methods: A narrative review with a structured literature search was conducted. Two conceptual blocks were explored: global disparities and access to care in hemophilia, and recent therapeutic advances, including non-replacement therapies, extended half-life products, and gene therapy. Retrieved records were screened using Rayyan, and a structured workflow diagram was used to summarize the literature identification and selection process. A descriptive analysis was also performed to identify representative authors, institutions, and geographic patterns in hemophilia research. Results: The evidence shows substantial global disparities in diagnosis, access to treatment, healthcare infrastructure, and research production. Scientific output remains concentrated in high-income countries, while low- and middle-income regions are underrepresented. Advanced therapies consistently reduce bleeding rates and treatment burden, but concerns remain regarding access, affordability, durability, breakthrough bleeding, and long-term structural joint outcomes. Musculoskeletal complications, including subclinical bleeding and hemophilic arthropathy, remain clinically relevant despite improved hematologic control. Conclusions: The current paradigm shift in hemophilia care is not uniformly experienced worldwide. Addressing global disparities requires not only expanding access to advanced therapies, but also strengthening research capacity, implementing multidisciplinary care models, and integrating scalable interventions such as physiotherapy, patient education, and simplified diagnostic tools. Accessible musculoskeletal assessment strategies may help improve early detection, functional outcomes, and equity of care in resource-limited settings.<\/jats:p>","DOI":"10.3390\/hematolrep18030042","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:03:23Z","timestamp":1782263003000},"page":"42","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Global Gap in the Hemophilia Paradigm Shift: Disparities in Research, Care, and Musculoskeletal Health"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2590-284X","authenticated-orcid":false,"given":"Felipe","family":"Querol-Giner","sequence":"first","affiliation":[{"name":"PTinMotion Research Group, Department of Physiotherapy, University of Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Querol-Giner","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Hospital Cl\u00ednico Universitario de Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4449-0174","authenticated-orcid":false,"given":"Ana","family":"Chimeno-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Physiotherapy, University of Valencia, 46010 Valencia, Spain"},{"name":"Hemophilia Association of the Valencian Community (ASHECOVA), 46018 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8737-1338","authenticated-orcid":false,"given":"Pilar","family":"Alberola-Zorrilla","sequence":"additional","affiliation":[{"name":"Hemophilia Association of the Valencian Community (ASHECOVA), 46018 Valencia, Spain"},{"name":"Department of Anatomy and Human Embryology, University of Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0841-5767","authenticated-orcid":false,"given":"Sof\u00eda","family":"P\u00e9rez-Alenda","sequence":"additional","affiliation":[{"name":"PTinMotion Research Group, Department of Physiotherapy, University of Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-8211","authenticated-orcid":false,"given":"Santiago","family":"Bonanad","sequence":"additional","affiliation":[{"name":"Coagulation Disorders Unit, Department of Hematology, Hospital Universitario y Polit\u00e9cnico La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-2380","authenticated-orcid":false,"given":"Felipe","family":"Querol-Fuentes","sequence":"additional","affiliation":[{"name":"Department of Physiotherapy, University of Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"The Lancet Global Health (2024). The landscape for rare diseases in 2024. Lancet Glob. Health, 12, e341.","DOI":"10.1016\/S2214-109X(24)00056-1"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_4","first-page":"CD014544","article-title":"Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B","volume":"3","author":"Olasupo","year":"2026","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1182\/bloodadvances.2024014111","article-title":"Adeno-associated virus-based gene therapy for hemophilia A and B: A systematic review and meta-analysis","volume":"8","author":"Deshpande","year":"2024","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2012.02822.x","article-title":"WFH: Closing the global gap\u2014Achieving optimal care","volume":"18","author":"Skinner","year":"2012","journal-title":"Haemophilia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/hae.14673","article-title":"Theory of change and strategic priorities of the world federation of haemophilia","volume":"29","author":"Coffin","year":"2023","journal-title":"Haemophilia"},{"key":"ref_8","unstructured":"World Federation of Hemophilia (2025). Annual Global Survey 2024, World Federation of Hemophilia."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/hae.70213","article-title":"Key Findings From the World Federation of Haemophilia National Member Organization Survey on Women and Girls with Bleeding Disorders","volume":"32","author":"Coffin","year":"2026","journal-title":"Haemophilia"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wei, Z., Ou, L., Chai, S., Zhang, D., and Tang, G. (2025). Global trends in hemophilic arthropathy research: A bibliometric and visualization analysis. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1556906"},{"key":"ref_11","first-page":"e62817","article-title":"Improving Hemophilia Care in Low- and Middle-Income Countries: Addressing Challenges and Enhancing Quality of Life","volume":"16","author":"Perolla","year":"2024","journal-title":"Cureus"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14657","article-title":"How to assess, detect, and manage joint involvement in the era of transformational therapies: Role of point-of-care ultrasound","volume":"29","author":"Minno","year":"2023","journal-title":"Haemophilia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jth.15444","article-title":"Hemophilic arthropathy: Current knowledge and future perspectives","volume":"19","author":"Gualtierotti","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.59556\/japi.73.1055","article-title":"Unmet Needs in Hemophilia: A Narrative Review","volume":"73","author":"Jena","year":"2025","journal-title":"J. Assoc. Physicians India"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jtha.2023.12.027","article-title":"The underevaluated impacts of the therapeutic revolution of hemophilia on women and girls","volume":"22","author":"Hermans","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/jth.15311","article-title":"\u201cThey don\u2019t really take my bleeds seriously\u201d: Barriers to care for women with inherited bleeding disorders","volume":"19","author":"Arya","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e103112","DOI":"10.1136\/bmjopen-2025-103112","article-title":"Modelling US health equity impacts of emicizumab for severe haemophilia A: Aggregate distributional cost-effectiveness analysis","volume":"15","author":"Majda","year":"2025","journal-title":"BMJ Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/17474086.2026.2634281","article-title":"Gene therapy in the treatment of hemophilia A: A systematic review and meta-analysis","volume":"19","author":"Camelo","year":"2026","journal-title":"Expert Rev. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/hum.2023.208","article-title":"Efficacy and Safety of Adeno-Associated Virus-Based Clinical Gene Therapy for Hemophilia: A Systematic Review and Meta-Analysis","volume":"35","author":"Han","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/hae.70189","article-title":"Outcomes of Emicizumab Treatment for Haemophilia A Paediatric Patients: A Systematic Review With Meta-Analysis","volume":"32","author":"Bolou","year":"2026","journal-title":"Haemophilia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/17474086.2023.2293096","article-title":"Efficacy\/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: A systematic review and meta-analysis","volume":"16","author":"Muniz","year":"2023","journal-title":"Expert Rev. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/JBM.S490588","article-title":"Emerging Therapies in Hemophilia: Improving Equitable Access to Care","volume":"16","author":"Lewandowska","year":"2025","journal-title":"J. Blood Med."},{"key":"ref_23","first-page":"e239","article-title":"Haemophilia care in Europe\u2014A survey of 35 countries","volume":"19","author":"Noone","year":"2013","journal-title":"Haemophilia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1111\/hae.13263","article-title":"Haemophilia care in Europe\u2014A survey of 37 countries","volume":"23","author":"Mahony","year":"2017","journal-title":"Haemophilia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"102714","DOI":"10.1016\/j.rpth.2025.102714","article-title":"Global patterns of hemophilia drug trials, hemophilia care, and health care measures","volume":"9","author":"Fedewa","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/jwh.2022.0008","article-title":"Bleeding Disorders in Women and Girls: State of the Science and CDC Collaborative Programs","volume":"31","author":"Byams","year":"2022","journal-title":"J. Womens Health"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/hae.15088","article-title":"Driving improvement of diagnosis and awareness of heavy menstrual bleeding in women among physicians","volume":"30","author":"Kadir","year":"2024","journal-title":"Haemophilia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jtha.2024.12.004","article-title":"The history of women and hemophilia: A narrative review of evolving beliefs and testing practices","volume":"23","author":"Chaigneau","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/hae.15101","article-title":"Women and girls\u2019 participation in haemophilia clinical trials","volume":"30","author":"Fedewa","year":"2024","journal-title":"Haemophilia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/s13023-025-03957-0","article-title":"Knowledge mapping and bibliometric insights into gene therapy for rare inherited hematologic pathologies: Focus on sickle cell disease, hemophilia, and thalassemia","volume":"20","author":"Sweileh","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/hae.70147","article-title":"Haemophilia-Related Pain: A Bibliometric and Content Analysis of Research Trends and Key Themes","volume":"32","author":"Demirci","year":"2026","journal-title":"Haemophilia"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"El-Sayed, A.A., Reiss, U.M., Hanna, D., and Bolous, N.S. (2025). The role of public health in rare diseases: Hemophilia as an example. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1450625"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1538-7836.2006.01842.x","article-title":"Uncertain times for research on hemophilia and allied disorders","volume":"4","author":"Srivastava","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/hae.14592","article-title":"LongHest project: A prospective, observational study of extended half-life treatment in the musculoskeletal health of patients with severe haemophilia A","volume":"28","year":"2022","journal-title":"Haemophilia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103228","DOI":"10.1016\/j.rpth.2025.103228","article-title":"AOZORA study: 3-year interim analysis of safety and joint health in pediatric people with hemophilia A receiving emicizumab prophylaxis","volume":"9","author":"Shima","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1182\/bloodadvances.2023012285","article-title":"Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis","volume":"8","author":"Arcudi","year":"2024","journal-title":"Blood Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/hae.70012","article-title":"Impact of Systematic Joint Examination (Ultrasound, Functional and Physical) on Treatment Management Decisions in Patients with Haemophilia A in France: Final Data From the Prospective, Observational A-MOVE Study","volume":"31","author":"Drillaud","year":"2025","journal-title":"Haemophilia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1076029611418965","article-title":"Hemostasis research in India: Past, present, and future","volume":"18","author":"Ghosh","year":"2012","journal-title":"Clin. Appl. Thromb. Hemost."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/3\/42\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:46:40Z","timestamp":1782265600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/3\/42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["hematolrep18030042"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18030042","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}